
Please contact the doctor's office to verify that your insurance is accepted.
Dr. Inghirami is a practicing hematopathologist, who joined Weill Cornell Medical College in September 2013, as a Professor of Pathology and Laboratory Medicine. He has worked in the field of molecular biology for the last 2O years, defining the role and distribution of pathogenetic defects among lymphoproliferative disorders. Detection of any given abnormality is believed to improve diagnostic accuracy, and helps to provide clinical-proven stratification. Indeed, patient - specific genomic fingerprints will appropriately predict clinical outcomes, pin - point patient selective targets and thus tailor therapies. Restricted defects in individual leukemia/lymphoma patients provide the means...
CAR-T Targeting of Mutant Calreticulin Selectively Eradicates Myeloproliferative Neoplasm-Sustaining Stem Cells.
Correction: spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.
Establishment of Patient-Derived Xenotransplant and Cell Line Models for Canine B-Cell Lymphoma.